[go: up one dir, main page]

WO2022053993A3 - Treatments for sars-cov-2 infection (covid-19) - Google Patents

Treatments for sars-cov-2 infection (covid-19) Download PDF

Info

Publication number
WO2022053993A3
WO2022053993A3 PCT/IB2021/058235 IB2021058235W WO2022053993A3 WO 2022053993 A3 WO2022053993 A3 WO 2022053993A3 IB 2021058235 W IB2021058235 W IB 2021058235W WO 2022053993 A3 WO2022053993 A3 WO 2022053993A3
Authority
WO
WIPO (PCT)
Prior art keywords
covid
cov
sars
infection
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/058235
Other languages
French (fr)
Other versions
WO2022053993A2 (en
Inventor
Abhijit DESHMUKH
Abhijit Barve
Ravi Shankar
Prasanna C GANAPATHI
Akhilesh DIXIT
Amit ANTARKAR
Santanu Chakraborty
Ram A. Vishwakarma
Srivari CHANDRASEKHAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of WO2022053993A2 publication Critical patent/WO2022053993A2/en
Publication of WO2022053993A3 publication Critical patent/WO2022053993A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Active agent combinations are provided for the treatment and/or prevention of COVID-19.
PCT/IB2021/058235 2020-09-12 2021-09-10 Treatments for sars-cov-2 infection (covid-19) Ceased WO2022053993A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041039535 2020-09-12
IN202041039535 2020-09-12

Publications (2)

Publication Number Publication Date
WO2022053993A2 WO2022053993A2 (en) 2022-03-17
WO2022053993A3 true WO2022053993A3 (en) 2022-04-21

Family

ID=80631363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/058235 Ceased WO2022053993A2 (en) 2020-09-12 2021-09-10 Treatments for sars-cov-2 infection (covid-19)

Country Status (1)

Country Link
WO (1) WO2022053993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655240B1 (en) 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
CN117159556A (en) * 2022-05-27 2023-12-05 北京远大九和药业有限公司 Pharmaceutical composition and preparation method and application thereof
CN117777247A (en) * 2023-07-11 2024-03-29 山西锦波生物医药股份有限公司 Biosynthesis method of broad-spectrum antiviral polypeptide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089383A1 (en) * 2003-04-14 2004-10-21 Cipla Limited Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections
US20150238489A1 (en) * 2012-08-31 2015-08-27 Novadrug, Llc Heterocyclyl carboxamides for treating viral diseases
US20200230198A1 (en) * 2016-06-20 2020-07-23 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
US20200276262A1 (en) * 2017-10-06 2020-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Peptides for use in the treatment of viral infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089383A1 (en) * 2003-04-14 2004-10-21 Cipla Limited Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections
US20150238489A1 (en) * 2012-08-31 2015-08-27 Novadrug, Llc Heterocyclyl carboxamides for treating viral diseases
US20200230198A1 (en) * 2016-06-20 2020-07-23 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
US20200276262A1 (en) * 2017-10-06 2020-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Peptides for use in the treatment of viral infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMAT-SANTOS IGNACIO J.; SANTOS-MARTINEZ SANDRA; LóPEZ-OTERO DIEGO; NOMBELA-FRANCO LUIS; GUTIéRREZ-IBANES ENRIQUE; DEL VA: "Ramipril in High-Risk Patients With COVID-19", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 76, no. 3, 26 May 2020 (2020-05-26), AMSTERDAM, NL, pages 268 - 276, XP086213202, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2020.05.040 *
GAO YAN, YAN LIMING, HUANG YUCEN, LIU FENGJIANG, ZHAO YAO, CAO LIN, WANG TAO, SUN QIANQIAN, MING ZHENHUA, ZHANG LIANQI, GE JI, ZHE: "Structure of the RNA-dependent RNA polymerase from COVID-19 virus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 368, no. 6492, 15 May 2020 (2020-05-15), US , pages 779 - 782, XP055934767, ISSN: 0036-8075, DOI: 10.1126/science.abb7498 *
JANOWITZ TOBIAS, GABLENZ EVA, PATTINSON DAVID, WANG TIMOTHY C, CONIGLIARO JOSEPH, TRACEY KEVIN, TUVESON DAVID: "Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series", GUT MICROBIOTA, BRITISH MEDICAL ASSOCIATION , LONDON, UK, vol. 69, no. 9, 1 September 2020 (2020-09-01), UK , pages 1592 - 1597, XP055793948, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2020-321852 *
LOU YAN; LIU LIN; YAO HANGPING; HU XINGJIANG; SU JUNWEI; XU KAIJIN; LUO RUI; YANG XI; HE LINGJUAN; LU XIAOYANG; ZHAO QINGWEI; LIAN: "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 157, 25 October 2020 (2020-10-25), NL , XP086422279, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2020.105631 *
SAHA RUDRA P., SHARMA ASHISH RANJAN, SINGH MANOJ K., SAMANTA SAIKAT, BHAKTA SWARNAV, MANDAL SNEHASISH, BHATTACHARYA MANOJIT, LEE S: "Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 11, 19 January 2020 (2020-01-19), CH , XP055873445, ISSN: 1663-9812, DOI: 10.3389/fphar.2020.01258 *

Also Published As

Publication number Publication date
WO2022053993A2 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
AU2019384119A8 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
CA3246093A1 (en) Parp1 inhibitors and uses thereof
NO20052362L (en) Methods of administering dalbavancin for the treatment of bacterial infections
EP4119156A4 (en) Medicament for treatment and/or prevention of cancer
PH12022550130A1 (en) Enzyme inhibitors
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
EP4360649A4 (en) Medicament for treatment and/or prevention of cancer
EP3865140A8 (en) Preventive and/or therapeutic agent for clostridium difficile infection
WO2019236765A8 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
WO2023285654A3 (en) Compounds for the treatment of covid-19
WO2023240199A3 (en) Fitusiran for the treatment of hemophilia a and b
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
WO2022165434A3 (en) Fc-enhanced antibodies for prevention and treatment of ebola virus infection
MX2023005156A (en) Therapeutic ph responsive compositions.
WO2022063869A3 (en) Compounds for the treatment of viral infections
WO2021247916A8 (en) Azetidine and spiroazetidine compounds and uses thereof
EP4119160A4 (en) Medicament for treatment and/or prevention of cancer
EP4119157A4 (en) Medicament for treatment and/or prevention of cancer
WO2023034914A3 (en) Methods for the prevention and treatment of synucleinopathies
WO2023003951A3 (en) Compositions and methods for the treatment of herpes simplex virus infection
EP3782631A4 (en) Agent for prevention and/or treatment of pseudomonas aeruginosa infection
CA3243677A1 (en) Quercetin-based compositions for the treatment and prevention of ocular affections
WO2021202317A3 (en) Novel methods of using nitric oxide donor compounds for treatment of covid-19 and other infectious diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21866190

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202347025930

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21866190

Country of ref document: EP

Kind code of ref document: A2